← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Bionano Genomics, Inc. (BNGO) 10-Year Financial Performance & Capital Metrics

BNGO • • Industrial / General
HealthcareDiagnostics & ResearchLife Sciences Instrumentation & ToolsNext-Generation Sequencing Platforms
AboutBionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.Show more
  • Revenue $31M -14.8%
  • EBITDA -$90M +55.5%
  • Net Income -$112M +51.8%
  • EPS (Diluted) -88.13 +99.6%
  • Gross Margin 1.23% -95.3%
  • EBITDA Margin -291.65% +47.7%
  • Operating Margin -337.87% +43.3%
  • Net Margin -363.98% +43.5%
  • ROE -170.33% -26.6%
  • ROIC -73.88% +5.4%
  • Debt/Equity 0.77 -6.6%
  • Interest Coverage -359.80 -755.7%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 24.9%
  • ✓Trading at only 0.1x book value

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 8 (bottom 8%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y24.89%
3Y19.62%
TTM-13.84%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM71.58%

EPS CAGR

10Y-
5Y-
3Y-
TTM99.78%

ROCE

10Y Avg-170.92%
5Y Avg-93.21%
3Y Avg-96.28%
Latest-135.3%

Peer Comparison

Next-Generation Sequencing Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
BNGOBionano Genomics, Inc.15.47M1.52-0.02-14.79%-134.36%-77.49%0.77
ATLNAtlantic International Corp.135.19M2.31-0.6310.27%-22.66%
ILMNIllumina, Inc.22.2B145.30-18.89-2.93%16.4%29.53%3.19%1.10

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+6.79M9.51M12M10.13M8.5M17.98M27.8M36.12M30.78M
Revenue Growth %-0.4%0.26%-0.16%-0.16%1.11%0.55%0.3%-0.15%
Cost of Goods Sold+3.58M6.03M8.71M6.77M5.73M14.11M21.86M26.55M30.4M
COGS % of Revenue0.53%0.63%0.73%0.67%0.67%0.78%0.79%0.74%0.99%
Gross Profit+3.21M3.47M3.29M3.36M2.77M3.87M5.95M9.57M380K
Gross Margin %0.47%0.37%0.27%0.33%0.33%0.22%0.21%0.26%0.01%
Gross Profit Growth %-0.08%-0.05%0.02%-0.18%0.4%0.53%0.61%-0.96%
Operating Expenses+24.38M26.09M23.7M29.24M41.32M80.97M137.64M224.81M104.36M
OpEx % of Revenue3.59%2.74%1.98%2.89%4.86%4.5%4.95%6.22%3.39%
Selling, General & Admin12.95M14.08M14.22M20.16M058.49M88.6M94.96M51.85M
SG&A % of Revenue1.91%1.48%1.18%1.99%-3.25%3.19%2.63%1.68%
Research & Development11.43M12.01M9.48M9.08M10.26M22.48M49.05M54.03M24.8M
R&D % of Revenue1.68%1.26%0.79%0.9%1.21%1.25%1.76%1.5%0.81%
Other Operating Expenses-203.28K00031.07M0-223K75.82M27.7M
Operating Income+-21.17M-23.22M-20.42M-25.87M-38.55M-77.1M-131.7M-215.25M-103.98M
Operating Margin %-3.12%-2.44%-1.7%-2.55%-4.53%-4.29%-4.74%-5.96%-3.38%
Operating Income Growth %--0.1%0.12%-0.27%-0.49%-1%-0.71%-0.63%0.52%
EBITDA+-20.05M-21.71M-19.09M-24.75M-37.07M-73.73M-121.6M-201.54M-89.76M
EBITDA Margin %-2.95%-2.28%-1.59%-2.44%-4.36%-4.1%-4.37%-5.58%-2.92%
EBITDA Growth %--0.08%0.12%-0.3%-0.5%-0.99%-0.65%-0.66%0.55%
D&A (Non-Cash Add-back)1.12M1.5M1.32M1.13M1.48M3.37M10.1M13.71M14.23M
EBIT-18.37M-22.76M-17.1M-27.51M-37.05M-77.22M-130.41M-227.31M-111.69M
Net Interest Income+-470.07K-590.93K-1.38M-2.29M-2.52M-691K1.21M-1.81M1.81M
Interest Income00000236K1.51M3.31M2.1M
Interest Expense470.07K590.93K1.38M2.29M2.52M927K298K5.12M289K
Other Income/Expense2.33M-128K1.93M-3.92M-2.53M-1.05M986K-17.19M-8M
Pretax Income+-18.84M-23.35M-18.48M-29.79M-41.08M-78.15M-130.71M-232.43M-111.98M
Pretax Margin %-2.77%-2.46%-1.54%-2.94%-4.83%-4.35%-4.7%-6.44%-3.64%
Income Tax+12.92K18.55K15.51K21.05K29K-5.72M1.88M62K33K
Effective Tax Rate %1%1%1%1%1%0.93%1.01%1%1%
Net Income+-18.85M-23.37M-18.5M-29.82M-41.11M-72.44M-132.6M-232.49M-112.02M
Net Margin %-2.77%-2.46%-1.54%-2.94%-4.83%-4.03%-4.77%-6.44%-3.64%
Net Income Growth %--0.24%0.21%-0.61%-0.38%-0.76%-0.83%-0.75%0.52%
Net Income (Continuing)-18.85M-23.37M-18.5M-29.82M-41.11M-72.44M-132.6M-232.49M-112.02M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+0.000.00-94089.60-71662.20-14194.80-9421.20-16505.40-24516.00-88.13
EPS Growth %---0.24%0.8%0.34%-0.75%-0.49%1%
EPS (Basic)0.000.00-94089.60-71662.20-14194.80-9421.20-16505.40-24508.80-88.13
Diluted Shares Outstanding00201424177.23K470.53K491.66K580.55K1.9M
Basic Shares Outstanding00201424177.23K470.53K491.66K580.38K1.9M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+10.74M7.14M23.03M28.26M46.79M272.41M157.3M140.12M39.49M
Cash & Short-Term Investments5.25M1.02M16.52M17.31M38.45M250.61M113.19M66.77M9.47M
Cash Only5.25M1.02M16.52M17.31M38.45M24.57M5.09M17.95M9.17M
Short-Term Investments00000226.04M108.09M48.82M302K
Accounts Receivable1.85M3.35M4.51M6.33M2.77M5.32M7.5M9.66M4.77M
Days Sales Outstanding99.22128.73137.3228.23119.12108.0198.4197.6456.62
Inventory1.8M1.69M1.07M3.44M3.31M12.39M29.76M22.89M11.12M
Days Inventory Outstanding183.32102.5144.77185.71211.16320.5496.99314.71133.54
Other Current Assets802.5K550.06K458.82K457.06K462K1.38M2.41M36.09M12.32M
Total Non-Current Assets+4.05M3.01M1.78M1.95M13.66M104.69M150.2M74.28M37.18M
Property, Plant & Equipment4.05M3.01M1.78M1.95M4.91M20.93M28.96M32.48M24.32M
Fixed Asset Turnover1.68x3.16x6.75x5.20x1.73x0.86x0.96x1.11x1.27x
Goodwill00007.17M56.16M77.29M00
Intangible Assets00001.48M26.84M41.14M33.97M9.71M
Long-Term Investments000000000
Other Non-Current Assets0000103K749K2.81M7.83M3.15M
Total Assets+14.79M10.15M24.8M30.21M60.45M377.1M307.5M214.4M76.67M
Asset Turnover0.46x0.94x0.48x0.34x0.14x0.05x0.09x0.17x0.40x
Asset Growth %--0.31%1.44%0.22%1%5.24%-0.18%-0.3%-0.64%
Total Current Liabilities+9.36M16.65M4.52M26.37M8.95M21.84M35.88M100.03M37.34M
Accounts Payable792.33K2.3M1.35M2.7M2.93M10.77M12.53M10.38M6.96M
Days Payables Outstanding80.81139.3956.64145.56186.64278.63209.31142.7683.6
Short-Term Debt587.13K6.73M020.08M00069.8M20.36M
Deferred Revenue (Current)446.77K211.7K271K357.49K416K1000K888K800K1000K
Other Current Liabilities6.9M3.9M2.13M2.07M3.36M4.53M16.38M13.96M3M
Current Ratio1.15x0.43x5.09x1.07x5.23x12.47x4.38x1.40x1.06x
Quick Ratio0.95x0.33x4.85x0.94x4.86x11.91x3.55x1.17x0.76x
Cash Conversion Cycle201.7391.85125.44268.38143.64149.88386.09269.59106.56
Total Non-Current Liabilities+32.68M43.72M10.14M227.13K16.42M18.14M22.22M18.22M3.95M
Long-Term Debt6.05M09.03M016.32M0000
Capital Lease Obligations-25.42M00008.93M9.12M7.17M3.68M
Deferred Tax Liabilities25.42M00000000
Other Non-Current Liabilities-24.44M43.58M808.37K44.48K09.07M12.97M10.89M0
Total Liabilities42.05M60.37M14.67M26.59M25.37M39.98M58.1M118.25M41.3M
Total Debt+6.63M6.73M9.03M20.08M16.32M10.7M11.67M79.41M27.3M
Net Debt1.38M5.71M-7.49M2.77M-22.12M-13.88M6.58M61.47M18.12M
Debt / Equity--0.89x5.56x0.47x0.03x0.05x0.83x0.77x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-45.03x-39.29x-14.78x-11.32x-15.30x-83.17x-441.94x-42.05x-359.80x
Total Equity+-27.26M-50.23M10.14M3.61M35.08M337.12M249.4M96.16M35.38M
Equity Growth %--0.84%1.2%-0.64%8.71%8.61%-0.26%-0.61%-0.63%
Book Value per Share--50556.578515.47197.95716.46507.26165.6318.59
Total Shareholders' Equity-27.26M-50.23M10.14M3.61M35.08M337.12M249.4M96.16M35.38M
Common Stock781K3.43K19K29K3K00
Retained Earnings-30.9M-54.27M-72.76M-102.58M-143.68M-216.12M-348.71M-581.21M-693.23M
Treasury Stock0-4.04M0000000
Accumulated OCI-2.42M-3.92M-5.16M00-539K-1.12M23K27K
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-23.5M-20.82M-19.94M-29.53M-38.31M-71.93M-124.82M-125.18M-68.92M
Operating CF Margin %-3.46%-2.19%-1.66%-2.92%-4.51%-4%-4.49%-3.47%-2.24%
Operating CF Growth %-0.11%0.04%-0.48%-0.3%-0.88%-0.74%-0%0.45%
Net Income-18.85M-23.37M-18.5M-29.82M-41.11M-72.44M-132.6M-232.49M-112.02M
Depreciation & Amortization1.12M1.5M1.32M1.13M1.48M3.37M9.84M13.91M14.23M
Stock-Based Compensation130.64K382.83K1.31M1.35M1.55M9.72M22.42M15.18M9.74M
Deferred Taxes-3.01M479.01K-2.46M1.9M0-5.78M1.76M00
Other Non-Cash Items73.9K96.58K750.47K883.27K3.2M848K1.7M92.99M14.73M
Working Capital Changes-2.96M85.1K-2.37M-4.97M-3.44M-7.65M-27.94M-14.77M4.4M
Change in Receivables-856.1K-1.77M-900.12K-2.37M2.09M-493K-2.25M-2.3M4.14M
Change in Inventory-726.14K-336.05K-418.98K-3.64M-4.2M-15.93M-23.68M-4.15M-587K
Change in Payables-608.65K1.54M-954.38K1.36M-1.81M6.78M1.95M-2M-3.42M
Cash from Investing+-1.35M-1.02M-331.72K-61.06K-2.45M-278.06M82.77M24.16M73.84M
Capital Expenditures-1.35M-1.02M-331.72K-61.06K0-1.46M-3.2M-1.69M-103K
CapEx % of Revenue0.2%0.11%0.03%0.01%-0.08%0.12%0.05%0%
Acquisitions---------
Investments---------
Other Investing00000-607K618K00
Cash from Financing+25.43M17.61M35.78M30.38M61.9M336.11M23.01M113.81M-13.69M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing1.96K14.29K3.5K1M26.69M8.4M-85K-14.84M-10.06M
Net Change in Cash---------
Free Cash Flow+-24.85M-21.84M-20.28M-29.59M-38.31M-73.39M-128.12M-126.87M-69.03M
FCF Margin %-3.66%-2.3%-1.69%-2.92%-4.51%-4.08%-4.61%-3.51%-2.24%
FCF Growth %-0.12%0.07%-0.46%-0.29%-0.92%-0.75%0.01%0.46%
FCF per Share---101117.44-69728.55-216.19-155.97-260.58-218.54-36.28
FCF Conversion (FCF/Net Income)1.25x0.89x1.08x0.99x0.93x0.99x0.94x0.54x0.62x
Interest Paid00001.25M1.91M298K1.65M10.65M
Taxes Paid000000000

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)---182.46%-433.64%-212.46%-38.92%-45.21%-134.56%-170.33%
Return on Invested Capital (ROIC)---579.1%-429.75%-298.92%-34.4%-34.11%-78.06%-73.88%
Gross Margin47.32%36.55%27.41%33.18%32.61%21.55%21.38%26.49%1.23%
Net Margin-277.48%-245.82%-154.13%-294.34%-483.43%-402.84%-476.93%-643.74%-363.98%
Debt / Equity--0.89x5.56x0.47x0.03x0.05x0.83x0.77x
Interest Coverage-45.03x-39.29x-14.78x-11.32x-15.30x-83.17x-441.94x-42.05x-359.80x
FCF Conversion1.25x0.89x1.08x0.99x0.93x0.99x0.94x0.54x0.62x
Revenue Growth-39.93%26.26%-15.59%-16.06%111.47%54.62%29.9%-14.79%

Revenue by Segment

2018201920202021202220232024
Product11.46M9.47M6.23M11.7M20.43M26.73M27.01M
Product Growth--17.35%-34.25%87.73%74.65%30.85%1.05%
Consumable Revenue-2.71M3.14M5.81M6.73M11.16M12.77M
Consumable Revenue Growth--15.96%84.69%15.89%65.76%14.48%
Instrument Revenue-6.76M3.08M5.89M8.57M10M8.04M
Instrument Revenue Growth---54.38%90.83%45.52%16.72%-19.56%
Software Revenue----5.13M5.57M6.19M
Software Revenue Growth-----8.66%11.15%
Product and Service, Other537.56K655.06K2.27M600K700K9.39M3.77M
Product and Service, Other Growth-21.86%247.05%-73.61%16.67%1241.29%-59.87%

Revenue by Geography

2018201920202021202220232024
EMEA3.95M3.63M3.16M5.6M8.96M12.96M14.23M
EMEA Growth--8.27%-12.82%77.19%59.89%44.68%9.80%
Americas----13.86M18.02M13.65M
Americas Growth-----30.00%-24.26%
Asia Pacific3.45M1.47M850.93K3.05M4.98M5.13M2.89M
Asia Pacific Growth--57.36%-42.18%258.20%63.39%3.07%-43.64%
North America4.59M5.03M4.49M9.33M---
North America Growth-9.48%-10.75%107.80%---

Frequently Asked Questions

Growth & Financials

Bionano Genomics, Inc. (BNGO) reported $28.7M in revenue for fiscal year 2024. This represents a 323% increase from $6.8M in 2016.

Bionano Genomics, Inc. (BNGO) saw revenue decline by 14.8% over the past year.

Bionano Genomics, Inc. (BNGO) reported a net loss of $38.6M for fiscal year 2024.

Dividend & Returns

Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -170.3%. Negative ROE indicates the company is unprofitable.

Bionano Genomics, Inc. (BNGO) had negative free cash flow of $18.7M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.